You are here

LIDDS employs Head of Clinical Development

LIDDS has employed Charlotta Gauffin as Head of Clinical Development. Charlotta will join the company in March 2019 and be responsible for the Phase IIb clinical study for Liproca® Depot and the Phase I study to assess NanoZolid® in combination with docetaxel.

Charlotta Gauffin has extensive experience in clinical trials and project management from positions at Quintiles, Q-Med and Galderma. She holds a PhD in Organic Chemistry from the University of Uppsala. Charlotta will become a member of the LIDDS management team.

-LIDDS is pleased to welcome Charlotta to the management team. She has a solid background and broad experience in clinical trial management which will be important for finalizing the LPC-004 study and managing the NZ-DTX Phase I study. Charlotta will become a full-time employee and replace Carl-Gustaf Gölander who has made a significant contribution at LIDDS as Study Director and Clinical Program Leader, working part-time since 2015, says Monica Wallter, CEO.

-I look forward to contributing to LIDDS clinical development and to join the management team. The NanoZolid® technology is very exciting and creates many opportunities for both patients and the pharmaceutical industry, says Charlotta Gauffin.

Charlotta Gauffin is leaving a position as Senior Clinical Project Manager at Galderma.

For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, monica.wallter@liddspharma.com

                
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com

Attachment

Wednesday, February 6, 2019 - 03:09